INP2 Antibody

What is JPT2 protein and where is it expressed?

JPT2 (Jupiter microtubule associated homolog 2) is a protein with a canonical length of 190 amino acid residues and a molecular mass of 20.1 kDa in humans. It belongs to the JUPITER protein family and is localized in both the nucleus and cytoplasm. Research has shown that JPT2 is primarily expressed in liver, kidney, prostate, testis, and uterus tissues .

The protein is also known by several synonyms including HN1-like protein, hematological and neurological expressed 1-like protein, and CRAMP_1 like. Understanding its expression pattern is crucial for experimental design, particularly when selecting appropriate cell lines or tissue samples for your research.

What applications are JPT2 antibodies commonly used for?

JPT2 antibodies are primarily utilized in several key laboratory techniques:

• Immunofluorescence (IF): Widely reported as the most common application

• Western Blot (WB): For protein detection and quantification

• Immunohistochemistry (IHC): For tissue localization studies

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection

When selecting a JPT2 antibody, it's important to verify that it has been validated for your specific application. Research indicates that success in IF is often a good predictor of performance in WB and IP, which can help guide your selection process .

How do I validate the specificity of a JPT2 antibody?

Validating antibody specificity is crucial for experimental reliability. For JPT2 antibodies, consider these methodological approaches:

• Genetic validation (Gold standard): Use parental and CRISPR knockout (KO) cell lines. This approach has been shown to be significantly more reliable than orthogonal validation methods, particularly for immunofluorescence applications where genetic validation methods confirmed 80% of manufacturer claims versus only 38% for orthogonal methods .

• Western blot validation: Compare bands from wild-type samples with those from JPT2 knockout or knockdown samples. The specific 20.1 kDa band should disappear in the KO/KD samples.

• Immunofluorescence validation: Use a mosaic approach that images parental and KO cells in the same visual field to reduce imaging and analysis biases .

• Cross-reference validation: Check if the antibody has been validated in antibody characterization databases such as Antibody Registry, RRID Portal, or YCharOS .

What species reactivity can I expect from JPT2 antibodies?

When selecting an antibody for non-human research, verify the species reactivity claims and, ideally, seek validation data for your specific species of interest rather than assuming cross-reactivity.

How can I distinguish between different JPT2 isoforms?

JPT2 has up to three different isoforms reported . To distinguish between them:

• Select isoform-specific antibodies: Choose antibodies raised against epitopes unique to your isoform of interest. Review the epitope mapping information provided by manufacturers.

• Use Western blot analysis: Different isoforms can be distinguished by their molecular weights. Run high-resolution gels (12-15% polyacrylamide) to separate closely sized isoforms.

• Complementary detection methods: Consider using RT-PCR with isoform-specific primers alongside your antibody-based detection to confirm isoform identity.

• Knockout validation: Use CRISPR-based knockout models targeting specific isoforms as controls to verify antibody specificity.

When reporting research findings with JPT2, always specify which isoform(s) you've detected to avoid confusion in the literature.

What are the optimal conditions for Western blot detection of JPT2?

Based on antibody validation studies, consider these methodological details for optimal JPT2 Western blot protocols:

• Sample preparation:

  • For intracellular JPT2: Use standard cell lysis buffers (RIPA or NP-40 based)

  • For secreted forms: Collect and concentrate cell media

• Gel separation:

  • Use 12-15% polyacrylamide gels for better resolution of the 20.1 kDa protein

  • Include molecular weight markers spanning 10-25 kDa range

• Transfer conditions:

  • Optimize for small proteins: use PVDF membranes with 0.2 μm pore size

  • Short transfer times (60-90 minutes) at 100V or overnight at 30V

• Blocking and antibody incubation:

  • 5% non-fat dry milk or BSA in TBST is typically effective

  • Primary antibody dilutions typically range from 1:500 to 1:2000

  • Validate multiple antibodies side-by-side when possible

• Detection controls:

  • Always include wild-type and JPT2 knockout samples as positive and negative controls

  • For recombinant JPT2 experiments, include a tag-only control

What challenges might I encounter in immunoprecipitation experiments with JPT2?

Immunoprecipitation of JPT2 presents several methodological challenges:

• Antibody selection: Choose antibodies specifically validated for IP applications. According to validation studies, only a subset of antibodies that work in WB will successfully immunocapture their target in non-denaturing conditions .

• Protocol considerations:

  • Use non-denaturing cell lysates for intracellular JPT2

  • For secreted forms, concentrate the cell media before immunoprecipitation

  • Evaluate IP success using Western blot with a different, validated JPT2 antibody

• Potential complications:

  • JPT2's relatively small size (20.1 kDa) means it may be obscured by antibody light chains (~25 kDa) in Western blot analysis of IP samples

  • Solution: Use HRP-conjugated protein A/G or antibodies raised in different species for detection

• Protein interactions:

  • As a nuclear and cytoplasmic protein, JPT2 may form various protein complexes

  • Consider crosslinking approaches for capturing transient interactions

  • Use appropriate detergent conditions to preserve interactions of interest

How does subcellular localization affect JPT2 antibody selection and experimental design?

JPT2 is localized in both the nucleus and cytoplasm , which affects experimental approaches:

• Antibody selection considerations:

  • For IF studies: Select antibodies validated specifically for distinguishing nuclear versus cytoplasmic signals

  • For fractionation studies: Choose antibodies that recognize JPT2 in both native and denatured states

• Experimental design implications:

  • Include appropriate subcellular markers in IF studies (e.g., DAPI for nucleus, cytoskeletal markers for cytoplasm)

  • When performing subcellular fractionation, validate fraction purity with established markers

  • Consider how fixation methods might affect epitope accessibility in different cellular compartments

• Dynamic localization studies:

  • Design time-course experiments to track potential shuttling between compartments

  • Consider how experimental conditions might alter normal localization patterns

Understanding and accounting for the dual localization of JPT2 is essential for accurate interpretation of experimental results and avoiding compartment-specific artifacts.

What approaches can I use to validate JPT2 antibodies when CRISPR knockout cells are unavailable?

While CRISPR knockout validation is considered the gold standard , alternative approaches include:

• siRNA/shRNA knockdown:

  • Perform transient or stable knockdown of JPT2

  • Validate knockdown efficiency by qPCR

  • Compare antibody signal between knockdown and control samples

  • Limitation: Incomplete knockdown may result in residual signal

• Overexpression validation:

  • Express tagged JPT2 and confirm co-localization with antibody signal

  • Express JPT2 in low/non-expressing cell lines and observe signal increase

  • Limitation: May not detect non-specific binding to other proteins

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide before application

  • Specific signals should be blocked by peptide competition

  • Limitation: May not detect cross-reactivity with structurally similar proteins

• Orthogonal detection methods:

  • Compare results with orthogonal techniques (e.g., mass spectrometry)

  • Use multiple antibodies targeting different epitopes

  • Limitation: Less reliable than genetic approaches, confirming only 38% of IF applications versus 80% for genetic methods

How do I interpret conflicting results between different JPT2 antibodies?

Antibody discrepancies are common and require systematic troubleshooting:

• Validation status comparison:

  • Review the validation methodology for each antibody

  • Antibodies validated using genetic approaches (KO/KD) are generally more reliable than those validated with orthogonal methods, particularly for IF applications (80% vs 38% confirmation rate)

• Epitope differences:

  • Map the epitopes recognized by each antibody

  • Different results may reflect isoform specificity, post-translational modifications, or protein-protein interactions that mask certain epitopes

• Application-specific performance:

  • An antibody that works well in one application may fail in another

  • Success in IF has been shown to correlate with performance in WB and IP

• Resolution approach:

  • Test multiple antibodies in parallel using identical samples and protocols

  • Include appropriate positive and negative controls

  • Consider using a CRISPR knockout as the definitive control

What factors affect the reproducibility of JPT2 antibody experiments?

Reproducibility challenges with JPT2 antibodies may stem from several factors:

• Antibody quality variation:

  • Lot-to-lot variation in polyclonal antibodies

  • Antibody degradation during storage or handling

  • Solution: Document lot numbers and validate each new lot

• Technical variables:

  • Fixation methods significantly impact epitope accessibility

  • Blocking reagents may affect background and specificity

  • Antigen retrieval methods for IHC can alter results

  • Solution: Standardize and document all protocol steps

• Biological variables:

  • JPT2 expression levels vary across tissues

  • Cell cycle stage may affect subcellular localization

  • Solution: Use synchronized cells when appropriate

• Documentation and reporting:

  • Comprehensive reporting of Research Resource Identifiers (RRIDs)

  • Detailed methods sections including antibody dilutions and incubation conditions

  • Sharing of validation data through repositories like ZENODO or Antibody Registry

Following standardized antibody reporting guidelines and using antibodies with rigorous validation data significantly improves reproducibility.

How can I optimize JPT2 antibodies for multiplexed imaging applications?

Multiplexed imaging with JPT2 antibodies requires methodological considerations:

• Antibody selection criteria:

  • Choose antibodies raised in different host species to avoid secondary antibody cross-reactivity

  • Select antibodies with high signal-to-noise ratios for clear discrimination

  • Validate spectral separation when using fluorophores with similar emission spectra

• Technical optimization:

  • Sequential staining protocols may be necessary to avoid cross-reactivity

  • Test for potential antibody cross-talk or epitope blocking in multiplexed settings

  • Consider cyclic immunofluorescence methods for highly multiplexed imaging

• Controls for multiplexed systems:

  • Include single-stain controls to assess bleed-through

  • Use a mosaic of parental and JPT2 knockout cells to validate specificity in the multiplexed setting

  • Include absorption controls to verify antibody specificity

• Data analysis considerations:

  • Apply appropriate spectral unmixing algorithms

  • Establish quantitative thresholds for positive signal based on knockout controls

  • Use automated image analysis to reduce subjective interpretation

What approaches should I consider for studying post-translational modifications of JPT2?

Studying JPT2 post-translational modifications (PTMs) presents unique challenges:

• PTM-specific antibody selection:

  • Use antibodies specifically raised against the modified form of JPT2

  • Validate PTM-specific antibodies with appropriate controls (phosphatase treatment for phosphorylation, etc.)

  • Consider generating custom antibodies if commercial options are unavailable

• Enrichment strategies:

  • Immunoprecipitate total JPT2 followed by Western blotting with PTM-specific antibodies

  • Use phospho-enrichment (TiO₂, IMAC) or ubiquitin enrichment methods before mass spectrometry

  • Apply proximity labeling approaches to identify PTM-dependent interactions

• Validation approaches:

  • Generate site-specific mutants to confirm PTM sites

  • Use pharmacological modulators of the suspected modifying enzymes

  • Combine antibody-based detection with mass spectrometry for orthogonal validation

• Functional assessment:

  • Design experiments to correlate PTM status with subcellular localization

  • Assess how PTMs affect protein-protein interactions

  • Investigate PTM changes in response to cellular signaling

While specific information on JPT2 PTMs is limited in the available research, these methodological approaches provide a framework for investigation.

How can I distinguish between specific and non-specific binding of JPT2 antibodies?

Distinguishing specific from non-specific binding is a common challenge:

• Genetic controls (preferred method):

  • Use CRISPR knockout cells as negative controls

  • Specific signals should be absent in knockout samples

  • This approach has been shown to be the most reliable validation method

• Signal characteristics analysis:

  • Specific binding typically shows expected molecular weight and subcellular localization

  • Non-specific binding often presents as multiple unexpected bands or diffuse staining

  • For 9/65 targets in validation studies, researchers identified antibodies that detected the correct protein but also recognized unrelated proteins

• Comparative analysis:

  • Test multiple antibodies targeting different epitopes of JPT2

  • Consistent patterns across antibodies suggest specific binding

  • Document and report all bands observed, not just the expected one

• Quantitative assessment:

  • Measure signal-to-noise ratios under standardized conditions

  • Establish clear thresholds for positivity based on knockout controls

  • Consider dilution series to determine optimal antibody concentration

What resources are available for verifying JPT2 antibody quality?

Several resources can help assess antibody quality before purchase or use:

• Public validation databases:

  • Antibody Registry (AntibodyRegistry.org): Contains over 2.5 million commercial antibodies with assigned RRIDs

  • RRID Portal Community: Allows searching with terms like 'ycharos' to find characterized antibodies

  • YCharOS community on ZENODO: Contains comprehensive antibody characterization reports

• Literature assessment:

  • Search for publications using the specific antibody catalog number

  • Review methods sections for validation approaches used

  • Note that many published studies may not have used rigorous validation

• Manufacturer validation data:

  • Review the validation approach (genetic vs. orthogonal)

  • Request raw validation data when available

  • Note that validation with genetic approaches is more reliable (89% confirmation rate for WB, 80% for IF) compared to orthogonal approaches (80% for WB, 38% for IF)

• Collaborative resources:

  • BioImaging networks (Canada BioImaging, BioImaging North America, Global BioImaging)

  • Antibody validation consortia and working groups

  • Open science platforms for sharing validation data

Using these resources before selecting an antibody can save significant time and resources by avoiding unreliable reagents.